Analyst Soumit Roy of JonesTrading maintained a Buy rating on Bicara Therapeutics Inc., retaining the price target of $27.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Soumit Roy has given his Buy rating due to a combination of factors that highlight the potential of Bicara Therapeutics Inc.’s FICERA in combination with Keytruda. The recent presentation at ESMO Asia demonstrated significant tumor shrinkage in patients treated with 1500mg QW of FICERA, achieving deeper responses compared to lower doses. This suggests a promising efficacy profile that supports the ongoing pivotal Phase 2/3 trial.
Additionally, the consistent overall response rate and safety outcomes across different doses bolster confidence in the drug’s potential. The upcoming data from the 2000mg Q2W cohort could further enhance FICERA’s competitive position, especially if it shows improved efficacy without increased adverse effects. Despite being slightly behind a competitor in terms of timeline, the potential for dual drug approvals in the coming years strengthens the investment case for Bicara.
In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $36.00 price target.